June 12, 2017 / 7:39 AM / in 4 months

BRIEF-Probiodrug: encouraging results of the Phase 2a SAPHIR Study

June 12 (Reuters) - PROBIODRUG AG:

* ANNOUNCED ON SUNDAY ENCOURAGING RESULTS OF THE PHASE 2A SAPHIR STUDY

* ANNOUNCED FIRST LINE RESULTS OF ITS PHASE 2A SAPHIR STUDY IN EARLY AD PATIENTS

* RESULTS: A TOTAL OF 120 PATIENTS WERE RANDOMISED IN THE SAPHIR STUDY, 60 TO THE PLACEBO ARM AND 60 TO PQ912 ARM

* TREATMENT ARMS WERE WELL BALANCED WITH RESPECT TO AGE, GENDER, DISEASE SEVERITY AND APOE4 STATUS

* THE MEAN MMSE (MINI-MENTAL STATE EXAMINATION) SCORE AT BASELINE WAS 25.5 (MIN-MAX 21-30)

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below